Penn State hydrogel invisibility cloak diabetes therapy
Analysis based on 6 articles · First reported Aug 14, 2026 · Last updated Aug 26, 2026
The breakthrough could accelerate development of cell therapies for diabetes and other diseases, potentially reducing reliance on immunosuppressants and expanding the market for regenerative medicine. Companies and research institutions in the cell therapy and biomaterials space may see increased investment and interest.
Researchers at Pennsylvania State University developed a biomimetic zona pellucida (BZP) hydrogel coating that acts as an 'invisibility cloak' for transplanted insulin-producing islets, protecting them from immune attack without requiring immunosuppressants. In diabetic mice, BZP-coated islets restored healthy blood sugar within a week and maintained control for over 100 days, far exceeding uncoated therapies. The study, published in Nature Biomedical Engineering on August 14, 2026, was led by Yong Wang and first author Kyungsene Lee. The coating mimics the natural zona pellucida of egg cells, is only 20 micrometers thick, and is permeable to insulin. The team plans further studies and eventual clinical trials, with potential applications beyond diabetes in immunotherapy and regenerative medicine. The work was supported by the United States — National Institutes of Health and other funders.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard